Assessing the Impact of Nigerian Government Responses to Armed Banditry in Northwest Nigeria, 2017-2025. [PDF]
John Zinna A, Garba D.
europepmc +1 more source
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner +5 more
wiley +1 more source
Drug-resistant tuberculosis in conflict zones: a neglected global emergency. [PDF]
Abdi YH, Bashir SG.
europepmc +1 more source
Ethical Issues Conducting Research During War and Violent Conflict: A Review. [PDF]
O'Mathúna D, Anderson EE.
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
In defence of neutrality: has humanitarian self-critique gone too far? In response to the Lancet Commission on conflict, forced displacement and health. [PDF]
Nayna Schwerdtle P.
europepmc +1 more source
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source
Conflict-Related Disruption of Maternal Health Services: A Case Report of Maternal Death in Transit Due to Obstructed Labour in Somalia. [PDF]
Hassan AM, Hussein AM.
europepmc +1 more source
The forgotten foe returns: cholera's warning to a complacent world demanding urgent action. [PDF]
Cheema S +5 more
europepmc +1 more source

